Quiflapon

Drug Profile

Quiflapon

Alternative Names: L 686708; MK 0591; MK 591

Latest Information Update: 18 Sep 1995

Price : $50

At a glance

  • Originator Merck & Co
  • Class Indoles; Quinolines
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 18 Sep 1995 MK 591 is now called quiflapon
  • 19 Apr 1995 An in vivo study has been added to the pharmacokinetics section
  • 19 Apr 1995 A study in asthmatic patients has been added to the pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top